GLYC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GLYC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, GlycoMimetics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.
For the Biotechnology subindustry, GlycoMimetics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, GlycoMimetics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:
* The bar in red indicates where GlycoMimetics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.
GlycoMimetics (NAS:GLYC) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation
EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Thank you for viewing the detailed overview of GlycoMimetics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.
Edwin Rock | officer: Chief Medical Officer | 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Brian M. Hahn | officer: CFO | C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
Daniel M Junius | director | C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Bruce S Johnson | officer: SVP & Chief Commercial Officer | 9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850 |
Chinmaya Rath | officer: SVP and Chief Business Officer | 9708 MEDICAL CENTER DR., ROCKVILLE MD 20850 |
Invus Public Equities, L.p. | 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Invus Public Equities Advisors, Llc | 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Artal Group S.a. | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Artal International S.c.a. | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
S.a. Westend | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Administratiekantoor Westend Stichting | 10 percent owner | CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD |
Artal International Management S.a. | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Amaury Wittouck | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661 |
Scott D Sandell | 10 percent owner | |
Harout Semerjian | director, officer: Chief Executive Officer | 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950 |
From GuruFocus
By Business Wire Business Wire • 05-03-2023
By Business Wire Business Wire • 11-03-2022
By Business Wire Business Wire • 06-15-2023
By GuruFocus Research GuruFocus Editor • 05-20-2023
By Business Wire Business Wire • 02-15-2023
By Business Wire • 09-05-2023
By Business Wire • 09-06-2023
By Business Wire Business Wire • 11-02-2022
By Business Wire Business Wire • 05-31-2023
By Business Wire Business Wire • 07-27-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.